Five articles suggested by Yüksel Ürün

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.

He suggested following few must-read papers on X:

1. “PSA decline in mCRPC patients receiving 177Lu-PSMA-617 is linked to better survival & quality of life outcomes. The VISION trial shows PSA drop ≥90% reduces death risk by 87%.”
   
   Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial

Authors: Andrew J. Armstrong, Oliver Sartor, Johann de Bono, Kim Chi, Karim Fizazi , Bernd J. Krause, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Fred Saad, Tomasz M. Beer, Jiwen Wu, Osvaldo Mirante, Michael J. Morris

2. “Endometrial cancer diagnoses are rising in women under 50. This study highlights shared risk factors like BMI and diabetes across ages.
   More than HALF of cases in younger women were linked to these factors. Early education is crucial to reducing risk.”

Understanding risk factors for endometrial cancer in young women

Authors: Noah Charles Peeri, et al.

3. “Reprogramming tumors to present antigens like dendritic cells opens new doors for cancer immunotherapy. Adenoviral delivery of PU.1, IRF8, and BATF3 expands T cells, induces regressions, and establishes long-term immunity.
   Promising results in melanoma models pave the way for human trials.”

In vivo dendritic cell reprogramming for cancer immunotherapy

Authors: Ervin Ascic,  Fritiof Åkerström , Malavika Sreekumar Nair, André Rosa , Ilia Kurochkin, Olga Zimmermannova , Xavier Catena , Nadezhda Rotankova, Charlotte Veser , Michal Rudnik , Tommaso Ballocci , Tiffany Schärer , Xiaoli Huang , Maria de Rosa Torres , Emilie Renaud , Marta Velasco Santiago , Özcan Met , David Askmyr, Malin Lindstedt , Lennart Greiff , Laure-Anne Ligeon, Irina Agarkova , Inge Marie Svane , Cristiana F. Pires , Fábio F. Rosa , Carlos-Filipe Pereira.

4. “Cancer prevention and control improvements can significantly reduce the cancer burden. Tobacco control, better screening uptake, and addressing modifiable risks are key. Investment in new preventive agents and tech is crucial. “

Accelerating Progress to Reduce the Cancer Burden through Prevention and Control in the US

Authors: Katrina A B Goddard, Eric J Feuer, Asad Umar, Philip E Castle.

5. “Lorlatinib sets a new standard for ALK+ lung cancer, showing a 96% prevention of brain metastasis! 5-year PFS: 60%.”

New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non–Small Cell Lung Cancer Surpasses 5 years

Author: Christine M. Lovly.

Source: Yüksel Ürün/X

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.